Login to Your Account

Capital Formation Series, Part 3

Crowd-Funding is Coming, But Will it Be Niche Only?

By Trista Morrison

Monday, November 28, 2011
If H.R. 1070 is the capital formation bill likely to have the most immediate impact on biotech by providing an IPO alternative for small companies, then H.R. 2930 – which would let private firms raise up to $2 million through crowd-funding – might have the most long-term impact by helping start-ups bridge the valley of death.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription